GlaxoSmithKline plc announces Board and Committee changes

GlaxoSmithKline plc (the 'Company') today announces that Manvinder Singh (Vindi) Banga will join GSK's Board as a Non-Executive Director on 1 September 2015.

Mr Banga will succeed Sir Deryck Maughan as Senior Independent Director with effect from 5 May 2016. Sir Deryck will not seek re-election to the Company's Board at the Company's 2016 Annual General Meeting and will retire from the Board at the conclusion of the meeting.

Commenting on the appointment, Sir Philip Hampton, Chairman Designate, said: "I am delighted that Vindi is joining the Board.

"Vindi brings with him many years of experience and a track record of delivering outstanding performance in a highly competitive global consumer-focused industry which will be invaluable to GSK. My colleagues and I very much look forward to welcoming him to the Board."

Mr Banga worked for Unilever plc from 1977 to 2010 in a number of senior positions. In his last role at Unilever, he was President of the Global Foods, Home & Personal Care businesses, as well as being member of the Unilever Executive Board. He is currently a partner at the private equity fund Clayton, Dubilier & Rice and Chairman of the Supervisory Board of Mauser Group. He is also Senior Independent Director of Marks & Spencer Group plc and a Non-Executive Director at Thomson Reuters Corporation.

The Company also announces the following changes to its Board Committees with effect from 8 May 2015:

Urs Rohner, Non-Executive Director, has been appointed Chairman of the Remuneration Committee in anticipation of Tom de Swaan's retirement from the Company's Board at the conclusion of today's Annual General Meeting. Mr Rohner has been a member of the Remuneration Committee since his appointment to the Board on 1 January 2015.

Lynn Elsenhans, Non-Executive Director, has been appointed Chairman of the Corporate Responsibility Committee in anticipation of Sir Christopher Gent's retirement from the Board at the conclusion of today's Annual General Meeting. Ms Elsenhans has been a member of the Corporate Responsibility Committee since 1 October 2012.

V A Whyte

Company Secretary

Notes

1.     As Non-Executive Director of GSK, Mr Banga will receive standard annual fees of £85,000 per annum.  As for all GSK Non-Executive Directors, to enhance the link between directors and shareholders, at least 25% of his fees will be paid in the form of Ordinary Shares and allocated to a share account, and he will be able to invest part or all of the balance of his fees into the same share account. His fees will increase by a further £30,000 from 5 May 2016 when he becomes GSK's Senior Independent Director.

2.     The Board has determined that Mr Banga will be an independent Non-Executive Director, in accordance with the UK Corporate Governance Code. In addition, the Company confirms that there are no further disclosures to be made in connection with Mr Banga's appointment in accordance with Listing Rule 9.6.13R.

3.     Mr Rohner will receive an additional fee of £20,000 per annum to chair the Remuneration Committee.

4.     Ms Elsenhans will receive an additional fee of £20,000 per annum to chair the Corporate Responsibility Committee.

5.     With effect from 1 September 2015, the composition of the Board of GSK will be as follows:

Sir Philip Hampton       

Non-Executive Chairman

Sir Andrew Witty

Chief Executive Officer

Mr Simon Dingemans

Chief Financial Officer

Dr Moncef Slaoui 

Chairman, Global Vaccines

Professor Sir Roy Anderson

Independent Non-Executive Director

Mr Vindi Banga

Independent Non-Executive Director

Dr Stephanie Burns

Independent Non-Executive Director

Ms Stacey Cartwright

Independent Non-Executive Director

Ms Lynn Elsenhans

Independent Non-Executive Director

Ms Judy Lewent

Independent Non-Executive Director

Sir Deryck Maughan

Senior Independent Non-Executive Director

Dr Daniel Podolsky

Independent Non-Executive Director

Mr Hans Wijers

Independent Non-Executive Director

Mr Urs Rohner

Independent Non-Executive Director

GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.